Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Amiloxate is a small molecule organic compound used as a UV-B filter in sunscreen products. It is approved for use in the European Union and functions by selectively absorbing UV-B radiation (280–320 nm), thereby protecting skin from sunburn and long-term damage caused by ultraviolet radiation[1][3][6]. Amiloxate also exhibits anti-inflammatory activity—demonstrated by dose-dependent inhibition of edema in animal studies—and may possess antioxidant properties due to its structural similarity to cinnamic acid derivatives[1][6]. It acts as a free radical scavenger and has been proposed to have antimicrobial and antifibrotic potential[6]. In Europe, it is regulated as an active ingredient in cosmetic sunscreens; it has not been approved for over-the-counter sunscreen drug products in the United States but can be used as a UV absorber in cosmetics[3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on amiloxate.